Herpes Zoster Market Highlights:

Within the realm of infectious diseases, the Herpes Zoster Market occupies a significant position, addressing the complexities associated with the Varicella-Zoster Virus (VZV). This virus, responsible for both chickenpox and herpes zoster (shingles), poses a formidable challenge to public health worldwide. Amidst this landscape, efforts to combat the Herpes Zoster Market focus on understanding and managing the intricate dynamics of VZV infection. Varicella-Zoster Virus, the causative agent behind shingles, underscores the urgent need for effective prevention and treatment strategies. As researchers delve into the mechanisms of viral replication and immune evasion, the Herpes Zoster Market serves as a beacon of hope for individuals grappling with the debilitating consequences of VZV reactivation.

Herpes Zoster Market Size was valued at USD 0.15 billion in 2022 and is projected to grow from USD 0.16 Billion in 2023 to USD 0.27 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.90% during the forecast period (2023 - 2030).

Segmentation:

The global herpes zoster market is segmented into Diagnosis, application, end-users. The herpes zoster market, by Diagnosis, the market is segmented into laboratory testing and others. The laboratory testing segment is further categorized into immunofluorescent microscopy, real-time Polymerase Chain Reaction (PCR), serological testing. The treatment and prevention segment for the global herpes zoster market is divided into antiviral medications, narcotic medications, anti-inflammatory medications, antihistamines, anticonvulsants, capsaicin, numbing creams, gels, or patches, vaccines, and others. The route of administration segment for the global herpes zoster market is divided into oral, topical, and others. The end-user segment for the global herpes zoster market is divided into hospitals & clinics, diagnostic centers, research & academic institutes, home care settings, and others.

Regional Analysis:

The Americas is the largest in the market owing to the increasing government support for vaccination and the highly advanced healthcare facilities to address the growing incidence of the infection. The number of Americans aged 65 or above are projected to be doubled from 46 million to 98 million by 2060, with the subsequent rise in the older age group to nearly 24 percent of the total population from the present 15 percent. The disease is prevalent in older adults usually between 60 -80 years due to the weak immune system thereby providing an opportunity for future growth of the market.

European region is the second largest market over the forecast period due to factors such as the emerging innovative vaccines for disease management and rising incidence of herpes zoster will provide considerable growth opportunities to herpes zoster treatment companies in the European region. The growing prevalence of the herpes zoster infection in the regions such as Asia Pacific and Middle East & Africa which will emerge as the fastest growing regions in the global herpes zoster infection treatment market.

Key Players:

Some of the key herpes zoster market players are Astellas Pharma Inc. (Japan), Foamix Pharmaceuticals (Israel), Geneone Life Science (South Korea), GlaxoSmithKline plc (UK), Merck & Co. Inc. (US), NAL Pharma (Hong Kong), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), TSRL, Inc. and others.

For more information visit at MarketResearchFuture